James Gamble
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James Gamble has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Rider Betts
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
6 shared publications Yaver Bashir
Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
6 shared publicationsKim Rajappan
Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
5 shared publications- Neil Herring
Burdon Sanderson Cardiac Science Centre, Department of Physiology, Anatomy and Genetics University of Oxford Oxford UK
5 shared publications - Christopher Aldo Rinaldi
Guy’s and St Thomas’ Hospital & School of Biomedical Engineering and Imaging Sciences, King’s College London Department of Cardiology Westminster Bridge Road, London SE1 7EH
4 shared publications Kim Greaves
Sunshine Coast Hospital and Health Services, University of the Sunshine Coast, Queensland, Australia
4 shared publications
Latest Publications
- Open Access
- 21 June 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (6) , 100326
Prophylactic Permanent Pacemaker Implantation for Baseline Right Bundle Branch Block in Patients Undergoing Transcatheter Aortic Valve Replacement: Clinical Efficacy, Safety, and Long-Term Pacing Requirement
- 21 June 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (6) , 100326
Open AccessProphylactic Permanent Pacemaker Implantation for Baseline Right Bundle Branch Block in Patients Undergoing Transcatheter Aortic Valve Replacement: Clinical Efficacy, Safety, and Long-Term Pacing Requirement
- Open Access
- 11 April 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (7) , 2706-2721
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Aims: To conduct a meta‐analysis of randomized controlled trials (RCTs) to assess the effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on inflammatory biomarkers. Methods: Medline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity. Results: Thirty‐eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow‐up of 16 (12–24) weeks. Meta‐analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin‐6, tumour necrosis factor receptor‐1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C‐reactive protein (CRP), tumour necrosis factor‐α, plasminogen activator inhibitor‐1, fibroblast growth factor‐21 or monocyte chemoattractant protein‐1. Conclusions: Our analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP.
- 11 April 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (7) , 2706-2721
Open AccessThe effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Aims: To conduct a meta‐analysis of randomized controlled trials (RCTs) to assess the effect of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors on inflammatory biomarkers. Methods: Medline, Embase and the Cochrane Library were searched for RCTs investigating the effect of SGLT2 inhibitors on inflammatory biomarkers, adipokine profiles and insulin sensitivity. Results: Thirty‐eight RCTs were included (14 967 participants, 63.3% male, mean age 62 ± 8.6 years) with a median (interquartile range) follow‐up of 16 (12–24) weeks. Meta‐analysis showed that SGLT2 inhibitors significantly improved adiponectin, interleukin‐6, tumour necrosis factor receptor‐1 (vs. placebo alone: standardized mean difference [SMD] 0.34 [95% confidence interval {CI} 0.23, 0.45], mean difference [MD] −0.85 pg/mL [95% CI −1.32, −0.38], SMD −0.13 [95% CI −0.20, −0.06], respectively), leptin and homeostatic model assessment of insulin resistance index (vs. control: SMD −0.20 [95% CI −0.33, −0.07], MD −0.83 [95% CI −1.32, −0.33], respectively). There were no significant changes in C‐reactive protein (CRP), tumour necrosis factor‐α, plasminogen activator inhibitor‐1, fibroblast growth factor‐21 or monocyte chemoattractant protein‐1. Conclusions: Our analysis shows that SGLT2 inhibitors likely improve adipokine biomarkers and insulin sensitivity, but there is little evidence that SGLT2 inhibitors improve other inflammatory biomarkers including CRP.
- Open Access
Management of secondary mitral regurgitation: from drugs to devices
Severe secondary mitral regurgitation carries a poor prognosis with one in five patients dying within 12 months of diagnosis. Fortunately, there are now a number of safe and effective therapies available to improve outcomes. Here, we summarise the most up-to-date treatments. Optimal guideline-directed medical therapy is the mainstay therapy and has been shown to reduce the severity of mitral regurgitation in 40–45% of patients. Rapid medication titration protocols reduce heart failure hospitalisation and facilitate earlier referral for device therapy. The pursuit of sinus rhythm in patients with atrial fibrillation has been shown to significantly reduce mitral regurgitation severity, as has the use of cardiac resynchronisation devices in patients who meet guideline-directed criteria. Finally, we highlight the key role of mitral valve intervention, particularly transcatheter edge-to-edge repair (TEER) for management of moderate-severe mitral regurgitation in carefully selected patients with poor left ventricular systolic function, with a number needed to treat of 3.1 to reduce heart failure hospitalisation and 5.9 to reduce all-cause death. To slow the rapid accumulation of morbidity and mortality, we advocate a proactive approach with accelerated medical optimisation, followed by management of atrial fibrillation and cardiac resynchronisation therapy if indicated, then, rapid referral to the Heart Team for consideration of mitral valve intervention in patients with ongoing symptoms and at least moderate-severe mitral regurgitation. Mitral TEER has been shown to be ‘reasonably cost-effective’ (but not cost-saving) in the UK in selected patients, although TEER remains underused with only 6.5 procedures per million population (pmp) compared with Germany (77 pmp), Switzerland (44 pmp) and the USA (32 pmp).
Open AccessManagement of secondary mitral regurgitation: from drugs to devices
Severe secondary mitral regurgitation carries a poor prognosis with one in five patients dying within 12 months of diagnosis. Fortunately, there are now a number of safe and effective therapies available to improve outcomes. Here, we summarise the most up-to-date treatments. Optimal guideline-directed medical therapy is the mainstay therapy and has been shown to reduce the severity of mitral regurgitation in 40–45% of patients. Rapid medication titration protocols reduce heart failure hospitalisation and facilitate earlier referral for device therapy. The pursuit of sinus rhythm in patients with atrial fibrillation has been shown to significantly reduce mitral regurgitation severity, as has the use of cardiac resynchronisation devices in patients who meet guideline-directed criteria. Finally, we highlight the key role of mitral valve intervention, particularly transcatheter edge-to-edge repair (TEER) for management of moderate-severe mitral regurgitation in carefully selected patients with poor left ventricular systolic function, with a number needed to treat of 3.1 to reduce heart failure hospitalisation and 5.9 to reduce all-cause death. To slow the rapid accumulation of morbidity and mortality, we advocate a proactive approach with accelerated medical optimisation, followed by management of atrial fibrillation and cardiac resynchronisation therapy if indicated, then, rapid referral to the Heart Team for consideration of mitral valve intervention in patients with ongoing symptoms and at least moderate-severe mitral regurgitation. Mitral TEER has been shown to be ‘reasonably cost-effective’ (but not cost-saving) in the UK in selected patients, although TEER remains underused with only 6.5 procedures per million population (pmp) compared with Germany (77 pmp), Switzerland (44 pmp) and the USA (32 pmp).
- Open Access
- 11 October 2022
- Published by Elsevier in Clinical Medicine
- Vol. 22 (4) , 59-60
A tertiary care ambulatory heart failure pathway managing one-third of all admissions including older patients with similar quality to inpatient management
An ambulatory HF pathway was established in a ‘medical’ SDEC unit supported by a specialist HF team and a Hospital At Home service providing intravenous diuretic therapy, clinical assessment and point-of-care diagnostics. Data were collected on every index HF admission as part of the National Heart Failure Audit, and as a service evaluation.
- 11 October 2022
- Published by Elsevier in Clinical Medicine
- Vol. 22 (4) , 59-60
Open AccessA tertiary care ambulatory heart failure pathway managing one-third of all admissions including older patients with similar quality to inpatient management
An ambulatory HF pathway was established in a ‘medical’ SDEC unit supported by a specialist HF team and a Hospital At Home service providing intravenous diuretic therapy, clinical assessment and point-of-care diagnostics. Data were collected on every index HF admission as part of the National Heart Failure Audit, and as a service evaluation.
- 1 July 2018
- Published by Elsevier in Heart Rhythm
- Vol. 15 (7) , 1017-1022
Endocardial left ventricular pacing across the interventricular septum for cardiac resynchronization therapy: Clinical results of a pilot study
- 1 July 2018
- Published by Elsevier in Heart Rhythm
- Vol. 15 (7) , 1017-1022
Endocardial left ventricular pacing across the interventricular septum for cardiac resynchronization therapy: Clinical results of a pilot study
- Open Access
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i117
687Cardiomyoapthic aetiology affects the distribution of endocardial electrical latency; results from a multi-centre registry
Background: Biventricular endocardial (BIV ENDO) pacing may offer a potential benefit over standard CRT, especially in non-responders however the optimal left ventricular endocardial (LV ENDO) pacing site displays marked inter and intra-patient variability. Identifying and targeting late activating, viable tissue appears important.
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i117
Open Access687Cardiomyoapthic aetiology affects the distribution of endocardial electrical latency; results from a multi-centre registry
Background: Biventricular endocardial (BIV ENDO) pacing may offer a potential benefit over standard CRT, especially in non-responders however the optimal left ventricular endocardial (LV ENDO) pacing site displays marked inter and intra-patient variability. Identifying and targeting late activating, viable tissue appears important.
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i103-i104
533Does targeting the site of maximal electrical delay result in the optimal haemodynamic improvement; results from an international multi-centre registry
Background: Biventricular endocardial (BIV ENDO) pacing may offer a potential benefit over standard CRT, especially in non-responders however the optimal left ventricular endocardial (LV ENDO) pacing site displays marked inter and intra-patient variability. Identifying and targeting late activating, viable tissue appears important.
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i103-i104
533Does targeting the site of maximal electrical delay result in the optimal haemodynamic improvement; results from an international multi-centre registry
Background: Biventricular endocardial (BIV ENDO) pacing may offer a potential benefit over standard CRT, especially in non-responders however the optimal left ventricular endocardial (LV ENDO) pacing site displays marked inter and intra-patient variability. Identifying and targeting late activating, viable tissue appears important.
- Open Access
- 1 February 2017
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 3 (2) , 107-116
Cost-Effectiveness Analysis of Quadripolar Versus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator Therapy in a Large, Multicenter UK Registry
- 1 February 2017
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 3 (2) , 107-116
Open AccessCost-Effectiveness Analysis of Quadripolar Versus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator Therapy in a Large, Multicenter UK Registry
- Open Access
- 1 January 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (1) , 73-81
Endocardial left ventricular pacing for cardiac resynchronization: systematic review and meta-analysis
Endocardial left ventricular (LV) pacing for Cardiac Resynchronization Therapy has been proposed as an alternative to conventional LV lead placement via the coronary sinus. In order to assess the relative benefits and risks of this technique, we have performed a meta-analysis of published reports. A systemic search was performed using online databases to identify studies of lead-based endocardial pacing. A random-effects meta-analysis was performed, to assess the rate of complications and clinical response (defined as ≥1 decrease in NYHA class). We selected 23 studies, including 384 patients. The trans-atrial septal technique was used in 20 studies, 1 used the trans-ventricular apical technique, and 2 used the trans-ventricular septal technique. Mean age was 66 years, male 66%, EF 26%, NYHA class 3.0. Procedural success rates were over 95% in all studies. Clinical response was reported by 16 studies for 262 patients, giving a response estimate of 82% (95% CI 71–89%). There was significant heterogeneity, and response in the only large study was 59%. Thromboembolic (TE) complications were reported by all studies, over 22 ±32 months follow up. The rate of stroke was 2.5 events per 100 patient years (95% CI 1.5–4.3), and TIA 2.6 (1.1–6.1). The mortality rate was 4.5 (1.5–13.6) per 100 patient years. LV endocardial pacing appears to be a viable technique when conventional lead placement is not possible. Response rates were heterogeneous but comparable with conventional CRT. There is likely to be a small increase over expected rates of stroke, although included patients were high risk.
- 1 January 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (1) , 73-81
Open AccessEndocardial left ventricular pacing for cardiac resynchronization: systematic review and meta-analysis
Endocardial left ventricular (LV) pacing for Cardiac Resynchronization Therapy has been proposed as an alternative to conventional LV lead placement via the coronary sinus. In order to assess the relative benefits and risks of this technique, we have performed a meta-analysis of published reports. A systemic search was performed using online databases to identify studies of lead-based endocardial pacing. A random-effects meta-analysis was performed, to assess the rate of complications and clinical response (defined as ≥1 decrease in NYHA class). We selected 23 studies, including 384 patients. The trans-atrial septal technique was used in 20 studies, 1 used the trans-ventricular apical technique, and 2 used the trans-ventricular septal technique. Mean age was 66 years, male 66%, EF 26%, NYHA class 3.0. Procedural success rates were over 95% in all studies. Clinical response was reported by 16 studies for 262 patients, giving a response estimate of 82% (95% CI 71–89%). There was significant heterogeneity, and response in the only large study was 59%. Thromboembolic (TE) complications were reported by all studies, over 22 ±32 months follow up. The rate of stroke was 2.5 events per 100 patient years (95% CI 1.5–4.3), and TIA 2.6 (1.1–6.1). The mortality rate was 4.5 (1.5–13.6) per 100 patient years. LV endocardial pacing appears to be a viable technique when conventional lead placement is not possible. Response rates were heterogeneous but comparable with conventional CRT. There is likely to be a small increase over expected rates of stroke, although included patients were high risk.
- 1 March 2016
- Published by SAGE Publications in Journal of Health and Human Services Administration
- Vol. 39 (1) , 141-159
An Overview of the Efficacy of the 12-Step Group Therapy for Substance Abuse Treatment
This study was designed to determine if 12-Steps groups efficacy for substance abuse treatment significantly improve abstinence rates of heroin addicts in the short run and long run (1-year and 5-year period); and if abstinence rates are found to be lower for heroin addicts that have attended 12-Step groups at the 1-year mark, and if similar results would be expected at the 5-year mark. Secondary data from the Inter-University Consortium of Political and Social Research (ICPSR) was extracted and analyzed for the aforementioned hypothesis. Using SSPS to test the research hypothesis for the 1 -Year Follow Up, the chi-square test shows a p-value below of .10, and the analysis determined that there was significant evidence to support the hypothesis that cases in a 12-Steps or self-help program have a higher success than cases not in a program for the 1 -year follow up. For 5-Year Follow Up, the cases that attended a 12-Step program or a self-help program and about 27% went on to use heroin during the last 12 months compared to 34% cases that did not go to a program.
- 1 March 2016
- Published by SAGE Publications in Journal of Health and Human Services Administration
- Vol. 39 (1) , 141-159
An Overview of the Efficacy of the 12-Step Group Therapy for Substance Abuse Treatment
This study was designed to determine if 12-Steps groups efficacy for substance abuse treatment significantly improve abstinence rates of heroin addicts in the short run and long run (1-year and 5-year period); and if abstinence rates are found to be lower for heroin addicts that have attended 12-Step groups at the 1-year mark, and if similar results would be expected at the 5-year mark. Secondary data from the Inter-University Consortium of Political and Social Research (ICPSR) was extracted and analyzed for the aforementioned hypothesis. Using SSPS to test the research hypothesis for the 1 -Year Follow Up, the chi-square test shows a p-value below of .10, and the analysis determined that there was significant evidence to support the hypothesis that cases in a 12-Steps or self-help program have a higher success than cases not in a program for the 1 -year follow up. For 5-Year Follow Up, the cases that attended a 12-Step program or a self-help program and about 27% went on to use heroin during the last 12 months compared to 34% cases that did not go to a program.